Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy.

作者: Mario Airoldi , Antonella De Stefani , Sara Marchionatti , Fulvia Pedani , Pietro Gabriele

DOI: 10.1002/HED.1034

关键词:

摘要: Background We have shown that rIL-2 administration in recurrent head and neck cancers induces a tumor-specific T-lymphocyte reactivity tumor regression; pilot study we safe effective of rIL2 after cisplatin + 5-fluorouracil. Long-term results are not known. Methods Thirty patients with recurrent-persistent cancer were treated (100 mg-m2) d.1,5-fluorouracil (1 gr-m2-d c.i. 96 h), SQ (4.5 M IU day 8 to 12 15 19) every 3 weeks. Results The overall response rate was 53.3% (95% CI; 34.4–72.3%): 26.6% complete (CR) (8 patients) partial (PR) patients); 6 had SD (20%), PD (26.6%). The median follow-up 36 months (range, 28–44).The CR duration is 16.2 (8.5–39+); the survival this group has been reached. PR 7.2 (3–10); 13.3 (10–26). 14 months. Conclusions The most impressive finding very long CRs patients. This outcome reported other IL-2 therapy. © 2001 John Wiley & Sons, Inc. Head Neck 23: 298–304, 2001.

参考文章(27)
D Khayat, C Borel, J M Tourani, A Benhammouda, E Antoine, O Rixe, E Vuillemin, P A Bazex, L Thill, R Franks, Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. Journal of Clinical Oncology. ,vol. 11, pp. 2173- 2180 ,(1993) , 10.1200/JCO.1993.11.11.2173
Daniel R. Vlock, Carl H. Snyderman, Jonas T. Johnson, Eugene N. Myers, David E. Eibling, John S. Rubin, John M. Kirkwood, Janice P. Dutcher, George L. Adams, Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. Journal of Immunotherapy. ,vol. 15, pp. 134- 139 ,(1994) , 10.1097/00002371-199402000-00007
Stimson P. Schantz, Isaiah Dimery, Scott M. Lippman, Gary L. Clayman, Candice Pellegrino, Rudolfo Morice, A phase II study of interleukin-2 and interferon-alpha in head and neck cancer Investigational New Drugs. ,vol. 10, pp. 217- 223 ,(1992) , 10.1007/BF00877250
P. Lissoni, S. Barni, A. Ardizzoia, S. Crispino, F. Paolorossi, C. Archili, M. Vaghi, G. Tancini, Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. European Journal of Cancer. ,vol. 28, pp. 92- 96 ,(1992) , 10.1016/0959-8049(92)90393-G
G Cortesina, A De Stefani, E Galeazzi, GP Cavallo, F Badellino, G Margarino, C Jemma, G Forni, Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. British Journal of Cancer. ,vol. 69, pp. 572- 576 ,(1994) , 10.1038/BJC.1994.104
Tadahito Saito, Jyunichi Yoda, Toshihide Tabata, Local administration trials of interleukin-2 for head and neck cancer. Auris Nasus Larynx. ,vol. 18, pp. 169- 178 ,(1991) , 10.1016/S0385-8146(12)80221-5
Harold Wanebo, Dilshad Blackinton, Tracey Weigel, Peter Turk, Shashi Mehta, Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha☆ American Journal of Surgery. ,vol. 162, pp. 384- 387 ,(1991) , 10.1016/0002-9610(91)90154-6
S. P. Schantz, G. Clayman, T. Racz, E. A. Grimm, F. J. Liu, P. Lavedan, D. Taylor, C. Pellegrino, H. Savage, The In Vivo Biologic Effect of Interleukin 2 and Interferon Alfa on Natural Immunity in Patients With Head and Neck Cancer Archives of Otolaryngology-head & Neck Surgery. ,vol. 116, pp. 1302- 1308 ,(1990) , 10.1001/ARCHOTOL.1990.01870110074009
Helen E. Heslop, Andrew S. Duncombe, Joyce E. Reittie, Concha Bello-Fernandez, David J. Gottlieb, H. Grant Prentice, Atul B. Mehta, A. Victor Hoffbrand, Malcolm K. Brenner, Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. British Journal of Haematology. ,vol. 77, pp. 237- 244 ,(1991) , 10.1111/J.1365-2141.1991.TB07983.X
Kazunori Yoneda, Tetsuya Yamamoto, Eisaku Ueta, Tokio Osaki, Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-γ in oral cancer patients Journal of Clinical Immunology. ,vol. 12, pp. 289- 299 ,(1992) , 10.1007/BF00918153